Company new treatment for multiple sclerosis Tecfidera generics in Europe's challenge, pressure and its pricing and market share, according to citigroup analyst downgraded its rating on the stock.
Dr, an analyst at yalong Werber said in a research report, he still like drugs, but he did not think the European drug administration will provide data protection regulation. This will prevent other companies reference data when they submit their application for generic drugs.
Tecfidera is a pill taken once a day, analysts expect it to be a leader in the treatment of multiple sclerosis. The us food and drug administration for approval, in late march. Werber said, drugs launched in the United States should turn out better than expected, and could tally Tecfidera $$42.2 billion in sales this year.
Werber announced after the market closed on Tuesday in a report wrote: "a big fan of our drugs in the United States".
But analysts said the stock had a good run so far this year - as of Tuesday's shares rose more than 50% respectively, and its high price, attack on p/e ratio reflects investor expectations, rather than a negative surprise. He shares his rating to "neutral", from "buy".
"We will look for a better entry point, in order to obtain more constructive stock again, once the risk Tecfidera face become clear or stocks in Europe after the correction," the analysts wrote.
Werber proposed its biological genetic stock rating to "buy" from "neutral" in February.



Other News:
Ahead of the Bell: Analyst lowers Biogen rating
American who leaked NSA secrets is a free man in Hong Kong
Anti-G8 protests aim for London's Canary Wharf banking district
Turkish PM to meet Istanbul park protesters
FDA backs new for Amgen drug for rare bone tumors
Seatbelts could have prevented 3 Boston U deaths
Insight: The big money bails on Argentina - again
Crackdown filling NKorean prisons with defectors